Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) climbed about 3.5% after the company released encouraging interim results from its Phase 1/2 clinical trial evaluating MRT-2359 alongside enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).
The clinical-stage biotech said patients with androgen receptor (AR) mutations achieved a 100% PSA response rate and a 100% disease control rate. Of the four patients in this subgroup, two recorded partial responses under RECIST criteria, while the remaining two experienced stable disease. Across the broader group of 14 evaluable patients, the overall disease control rate was reported at 64%.
MRT-2359, an oral molecular glue degrader designed to target GSPT1, showed a favorable tolerability profile when used in combination with enzalutamide. Most treatment-related side effects were mild to moderate gastrointestinal events, classified as Grade 1 or 2.
“We continue to be highly encouraged by the clinical activity observed with MRT-2359 in combination with enzalutamide in heavily pretreated mCRPC patients, a population with limited therapeutic options,” said Markus Warmuth, CEO of Monte Rosa Therapeutics.
The trial enrolled 20 patients with advanced, heavily pretreated CRPC. Among them, 75% had previously received a second-generation AR inhibitor, 80% had been treated with taxane-based chemotherapy, and 55% had received Pluvicto.
Building on these findings, Monte Rosa plans to launch a signal-confirming Phase 2 study in 2026 that will assess MRT-2359 in combination with a second-generation AR inhibitor specifically in mCRPC patients harboring AR mutations. Updated clinical data are expected to be presented at the ASCO Genitourinary Cancers Symposium in February 2026.
Separately, the company said it also intends to share interim Phase 1 results for MRT-8102, its NEK7-targeting molecular glue degrader being developed for inflammatory diseases, in early 2026.